Trials / Terminated
TerminatedNCT04869228
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (actual)
- Sponsor
- Suzhou Kintor Pharmaceutical Inc, · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease
Detailed description
The subjects in the experimental group will receive GT0918 (200mg oral once-daily (QD) for 14 consecutive days) in addition to supportive treatment. The subjects in the control group will receive placebo (200mg oral once-daily (QD) for 14 consecutive days) in addition to supportive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GT0918 tablets or placebo | GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals |
Timeline
- Start date
- 2021-08-04
- Primary completion
- 2022-09-02
- Completion
- 2023-08-02
- First posted
- 2021-05-03
- Last updated
- 2023-08-18
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04869228. Inclusion in this directory is not an endorsement.